AzTrials
AzTrials

HealthyVIMOPEILNCT01038700

Circulating Endothelial Compartment During Normal and Pathological Aging

An observational study of Healthy, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This part of the project aims to describe changes in markers of vascular competence (Endothelial Microparticles Platelet (EMP), Circulating endothelial cells (CEC) and Circulating endothelial progenitors (EPC)) at different ages of lifespan both in physiological state and in response to hypoxia-induced vascular stress. Read more about this study

Who is it for?
Ages 10 to 90 years, men onlyHealthy volunteers can take part
Conditions the study is for
Healthy
How many people
84 participants
Where
1 siteFrance
Study dates
Dec 2008to Sep 2010
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 to 90 years
  • Men only
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: healthy volunteers

Who may be able to join

  • Healthy volunteers of 20-30 and 60-70 years old
  • Non smokers male
  • Biological test in normal values : lipids, glucose, TGO, TGT, alkaline phosphatases, gamma-GT, bilirubin, creatinine, ionogram, Ca++, albumin, proteins, WBC, platelets count, coagulation tests (APTT, PT, Fibrinogen).
  • Negative HIV1 and 2, HBV (Hbs antigen) and HCV serology.
  • Normal ECG 12 derivations, arterial pressure and cardiac frequency.

Who cannot join

  • Evaluative disease in the past 10 days
  • Hemorrhagic disorders
  • Treatments with antiplatelets agents, oral or injectable anticoagulant
  • Statins, glitazones, EPO, G-CSF
  • Frequent faintness
  • Blood donation in the 3 months preceding the study
Show all 10Show fewer
  • People in period of exclusion on the National File of the people who lend themselves to biomedical research
  • Refusal or linguistic or psychic incapacity to sign the enlightened consent
  • Biological parameters apart from the usual values of the healthy subject (Hb<10 g/dL, TGO/TGT > 2 times higher limit of normal values)
  • Prone not being able to subject to the constraints protocol (for example, not cooperating, incompetent to go to the visits of follow-up and probably incompetent to finish the study).

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hegp- Cic

    Paris

Other trials in France

About this study

Official title: Impact du Vieillissement (VI) Sur le Compartiment Circulant et Sur la Mobilisation (MO) Des progéniteurs endothéliaux (PE) Par ischémie Locale (IL) : étude Pilote

This part of the project aims to describe changes in markers of vascular competence (Endothelial Microparticles Platelet (EMP), Circulating endothelial cells (CEC) and Circulating endothelial progenitors (EPC)) at different ages of lifespan both in physiological state and in response to hypoxia-induced vascular stress.

Read the detailed description

Blood will be harvested in citrated or EDTA anticoagulant and processed within one hour for Endothelial Microparticles Platelet (EMP), Circulating endothelial cells (CEC) and Circulating endothelial progenitors (EPC) determination.

Methods for endothelial marker determination:

  • Endothelial Microparticles Platelet free plasma (PFP) will be prepared by a double step centrifugation of citrated blood at 1,500g for 15 min and 13,000 g for 2 min at room temperature. Then EMP will be enumerated by flow cytometry after labelling of PFP using monoclonal antibodies directed against endothelial antigens, such as CD144 (19). To investigate the proportion of EMP within the whole circulating MP, MP for platelet, leukocyte and erythrocyte origins will be determined using respectively, CD41, CD45, Glycophorin-directed antibodies, and the total number of phosphatidylserine expressing MP will be determined using AnnexinV binding.
  • CEC will be enumerated using the consensual methodology based on an immunomagnetic separation assay (20). CEC will be isolated from EDTA whole blood using magnetic beads coated with antibodies directed against the CD146 antigen. Isolated cells will be identify using additional criteria such as morphology, size higher than 15µm, cell rosettes bearing more than 5 beads, and expression of endothelial markers (lectin binding).
  • For EPC two complementary approaches will be used for determination:
  1. Flow cytometry after direct immunolabelling of whole blood or the mononuclear cell fraction using monoclonal antibodies and viability marker 7AAD. Due to the lack of specific markers for EPC and the great heterogeneity of cells that recovered the features of EPC21 flow cytometry analysis will include the numeration of different cell populations corresponding to differentiation state of EPC: CD34+CD133+ cells and CD34+KDR+ cells. The circulating haematopoietic progenitors CD34+CD45+ will be also numbered.-
  2. Clonogenic assays allowing the numeration of Colony Forming Unit after ex vivo culture of EPC including: - CFU-EC, which are EPC of myeloid subtype (also called early EPC) will be determined according to the previously described method of Hill et al. The non-adherent fraction of mononuclear cells will be plated on fibronectin coated dishes in Endocult® medium. the number of endothelial colonies will be counted after a 48h culture - High Proliferative Potential CFU, which are true angioblasts will be determined by Ingram's method (21). Mononuclear cells are plated on fibronectin-coated plates in EGM-2MV culture medium and late EPC colonies are enumerated after 10-15 days of culture. - three-dimension methyl cellulose assay in which the only added growth factor is VEGF. The CFU-EC are numbered after 14 days as usually performed for haematopoietic stem cells. Effect of hypoxia on the equilibrium between endothelial damage and repair According to Ingram, the normal vascular endothelium contains high proliferating potency EPC (22) suggesting that late EPC may also originate from the vessel wall. In addition, local hypoxia might also mobilize EPC (23).

We designed a protocol which specific aims are 1/ to test the effect of local hypoxia on the markers of endothelial damage/repair equilibrium 2/ to define whether in elderly patients, local ischemia can be used to mobilize EPC and to increase their proliferation potential compared to EPC isolated in resting conditions. Two groups of healthy volunteers aged 20-30 and 60-70 years from our cohorts will be submitted to forearm transient ischemia as described by Friedrich et al (23). Peripheral blood samples will be obtained before and after 10 min of venous occlusion performed with a cuff pressure midway between systolic and diastolic pressure (24). EPC, CEC and EMP will be enumerated according to the methods described supra and EPC will be tested for proliferating capacity at each time point. The arterial phenotype of conducting arteries will be evaluated, by the acute flow-mediated vasodilatation (FMD) and endothelium-independent vasodilatation (EIV) of the brachial artery (BA) in young and older healthy volunteers using a high-resolution echotracking system. The efficiency of venous occlusion will be evaluated by the release of t-PA by endothelial cells.

Conditions
Healthy
Keywords
Circulating endothelial compartment, microparticles, endothelial progenitors cells, circulating endothelial cells, transcriptome, aging, Healthy volunteers

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Analyse of CEC, EMP and EPC at different ages of lifespan both in physiological state and in response to an hypoxia- induced vascular stress

    Measured: 3 days

Secondary outcomes (1)
  1. Transcriptome analysis on EPC isolated from cord blood and peripheral blood from young and old adults

    Measured: end

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2009 (estimated)
  2. Study startDec 2008
  3. Primary completionAug 2009
  4. Study completionSep 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
84 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01038700
Sponsor's protocol ID
P070801
Acronym
VIMOPEIL
Status last verified
Sep 2015
First submitted
22 Dec 2009
Last updated
1 Oct 2015
Results posted
No
Data monitoring committee
No

Publications

  • HoWangYin KY, Loinard C, Bakker W, Guerin CL, Vilar J, d'Audigier C, Mauge L, Bruneval P, Emmerich J, Levy BI, Pouyssegur J, Smadja DM, Silvestre JS. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia. Stem Cells. 2014 Jan;32(1):231-43. doi: 10.1002/stem.1540.

    PubMed 24105925
  • Evrard SM, d'Audigier C, Mauge L, Israel-Biet D, Guerin CL, Bieche I, Kovacic JC, Fischer AM, Gaussem P, Smadja DM. The profibrotic cytokine transforming growth factor-beta1 increases endothelial progenitor cell angiogenic properties. J Thromb Haemost. 2012 Apr;10(4):670-9. doi: 10.1111/j.1538-7836.2012.04644.x.

    PubMed 22284809

Questions about this trial

What is this clinical trial studying?

An observational study of Healthy, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Analyse of CEC, EMP and EPC at different ages of lifespan both in physiological state and in response to an hypoxia- induced vascular stress (time frame: 3 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01038700, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2015.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
VIMOPEIL Clinical Trial NCT01038700 | AzTrials